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An obesity remedy for diabetes
For obese patients with type 2 diabetes, surgery may be 
the best bet.
PRACTICE CHANGER
Consider bariatric surgery for patients with 
diabetes who are obese; surgery is associat-
ed with higher remission rates than medical 
therapy, regardless of the amount of weight 
lost.1
StRENGtH oF RECoMMENDAtioN
B: Based on a single nonblinded randomized 
controlled trial (RCT).
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery ver-
sus conventional medical therapy for type 2 diabetes. N Engl J Med. 
2012;366:1577-1585.
IllusTRATIvE CAsE
a 43-year-old woman with a body mass in-
dex (Bmi) of 38 kg/m2  and a 5-year history 
of diabetes has a glycated hemoglobin 
(hba1c) of 8.5% despite the use of oral hypo-
glycemic agents. Should you talk to her about 
gastric bypass surgery to treat her diabetes?
Diet and exercise are the first steps in addressing diabetes, but these inter-ventions are often unsuccessful. The 
International Diabetes Federation (IDF) rec-
ommends consideration of bariatric surgery 
for patients who have a BMI >35 kg/m2 and 
diabetes that lifestyle modification and phar-
macotherapy have failed to control.2
Surgery for diabetes: 
is there ample evidence?
Until recently, the IDF’s recommendation 
was based on observational data and a single 
RCT that found increased resolution of diabe-
tes following various bariatric procedures.3-5 
In the study detailed in this PURL, Mingrone 
et al took another look.
sTuDY suMMARY
Surgery led to higher remission rates 
This single-center, nonblinded RCT com-
pared 2 malabsorptive procedures— 
Roux-en-Y gastric bypass and biliopancreatic 
diversion, a more complicated procedure not 
commonly performed—with medical ther-
apy.1 The primary outcome was the rate of 
diabetes remission at 2 years, defined as 
a fasting glucose level <100 mg/dL and an 
HbA1c <6.5%. Changes in BMI and cho-
lesterol levels were among the secondary 
endpoints.
To be eligible, patients had to be be-
tween the ages of 30 and 60 years and have 
a BMI ≥35 kg/m2, a history of type 2 diabetes 
≥5 years, and an HbA1c ≥7.0%. Exclusion 
criteria included a history of type 1 diabe-
tes, diabetes caused by an underlying dis-
ease or steroid treatment, previous bariatric 
surgery, pregnancy, diabetic complications, 
other severe medical conditions, and acute 
hospitalization. Both the gastric bypass and 
biliopancreatic diversion procedures were 
performed by independent surgical teams.
Participants (N=60) were evaluated at 
baseline and at 1, 3, 6, 9, 12, and 24 months 
after the intervention by a team that includ-
ed a dietician, a nurse, and a physician. All 
received a diet plan with daily exercise de-
signed by their team. Those in the medical 
therapy group had their medications titrated 
to reach a goal HbA1c <7%.  Pharmacother-
apy was stopped based on normalization of 
blood sugars or HbA1c <6.5%. 
Within 15 days postsurgery, patients in 
both surgical arms had their diabetes medi-
cations stopped based on their blood glucose 
levels. 
Do you  
recommend  
bariatric surgery 
as a treatment for 
diabetes?  
n  Yes, frequently
n  Occasionally
n  Rarely or never
n  No, but I plan to 





At 2 years, 75% of the patients in the gas-
tric bypass arm and 95% of the patients in 
the biliopancreatic diversion arm (number 
needed to treat=1.3 and 1, respectively) were 
considered to be in diabetes remission, de-
fined as a fasting blood sugar of <100 mg/dL 
and an HbA1c <6.5%  after one year without 
pharmacotherapy. (Notably, this differs from 
that of the American Diabetes Association, 
which requires an HbA1c <6.0% for classifi-
cation as complete remission.) None of the 
patients in the medical therapy arm was in 
remission at the 2-year mark. 
On average, blood sugars normalized 
for gastric bypass patients by 10±2 months, 
vs 4±1 months for biliopancreatic diver-
sion patients (P=.01). The average HbA1c at 
the end of 2 years was significantly different 
among all 3 groups (6.35%±1.42 for those 
undergoing gastric bypass, 4.95%±0.49 for 
the biliopancreatic diversion group, and 
7.69%±0.57 for the medical therapy group), 
as was the change in HbA1c from baseline 
(tAbLE).  Changes in BMI and the number of 
patients who achieved normalization of to-
tal cholesterol were similar for both surgical 
groups. Interestingly, neither baseline BMI 
nor amount of weight lost or pre-enrollment 
duration of diabetes were predictors of dia-
betes remission or normalization of fasting 
glucose levels.
There were no deaths associated with 
this study. There were 2 adverse events re-
quiring reoperation: an incisional hernia in a 
patient in the biliopancreatic diversion group 
and an intestinal obstruction in a patient in 
the gastric bypass group. Six patients in the 
biliopancreatic diversion arm developed 
metabolic abnormalities, including iron de-
ficiency anemia, hypoalbuminemia, osteo-
penia, and osteoporosis. In the gastric bypass 
arm, 2 patients developed iron deficiency 
anemia.
WHAT’s NEW?
Evidence of efficacy has grown
This is the first RCT to evaluate biliopancre-
atic diversion and only the second to evalu-
ate gastric bypass as strategies for controlling 
diabetes. Similar findings were demonstrat- 
ed at 12 months in an RCT of 150 obese pa-
tients with diabetes in which intensive medi-
cal therapy was compared with either gastric 
bypass or sleeve gastrectomy,6 published 
concurrently with the Mingrone study. Like 
the Mingrone study, this study found that for 
select patients with diabetes, surgery may 
lead to better outcomes than medical man-
agement alone.
CAvEATs
Long-term effect is still uncertain
The long-term efficacy of surgery as a way to 
manage diabetes remains uncertain. Patients 
in this study were followed for just 2 years 
and the outcomes were metabolic measures 
rather than morbidity and mortality. A re-
cent prospective observational study follow-
ing patients for 6 years after gastric bypass 
found that the rate of remission for diabe-
tes was 75% (95% confidence interval (CI), 
63%-87%) at 2 years but dropped to 62% 
(95% CI, 49%-75%) at 6 years7
A larger study (N=4047) of longer 
duration—the Swedish Obese Subjects (SOS) 
cohort study —found a considerably larger 
drop: The diabetes remission rate for those who 
had surgery went from 72% at 2 years to 36% 
at 10-year follow-up, but that was still higher 
than the 10-year remission rate (13%) for the 
matched controls.4 It is still not clear exactly 
how long diabetic remission lasts after bariat-
ric surgery or what effect a 10-year respite from 
the disease will have on the long-term morbid-
ity and mortality of patients with diabetes.
z Surgical risks. In small studies such as 
the one by Mingrone et al,1 it can be difficult 
to see the full extent of surgical complications. 
The much larger SOS study found low mor-
tality rates (0.25%). But 13% of those who un-
derwent bariatric surgery had postoperative 
complications (number needed to harm = 8), 
with 2.2% of patients requiring reoperation.4 
Additionally, women who become pregnant 
after bariatric surgery are at increased risk for 
internal hernias or bowel obstruction during 
pregnancy.8
Furthermore, malabsorptive-type sur-
geries are known to cause nutritional de-
ficiencies, leading to disorders including 
anemia and osteoporosis.6 Importantly, 
while women of childbearing-age who un-
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dergo bariatric surgery decrease their risk of 
developing gestational hypertension and ges-
tational diabetes, they are more likely to have 
nutritional deficiencies during pregnancy 
and to have children with these deficiencies.8
CHAllENGEs TO IMPlEMENTATION
the ideal candidate remains unclear
It is still not clear from this study which pa-
tients should be referred for bariatric surgery. 
Historically, BMI has been used as the main 
indication for bariatric surgery, but this and 
other, studies have found that remission of di-
abetes is independent of BMI and the amount 
of weight lost.9 A predictive 10-point Diabetes 
Surgery Score has recently been developed: 
It uses age, BMI, duration of diabetes, and 
C-peptide levels to predict the likelihood of di-
abetes remission after surgery.10 This scoring 
system has yet to be validated in non-Asian 
patients, and a threshold for recommending 
surgery has been not established. However, 
this tool indicates that younger patients with 
a shorter duration of diabetes (which was 
not a factor in the outcome of the Mingrone 
study) and no baseline use of insulin are most 
likely to benefit from surgery. Thus, these pa-
tients may be the ones we need to consider 
referring first. 
z Cost of surgery. Several studies have 
shown that bariatric surgery is cost-effective 
for the treatment of diabetes, and saves mon-
ey after approximately 5 years.11,12 However, 
patients with diabetes and obesity may be 
uninsured or underinsured, and have high 
out-of-pocket costs. One challenge will be to 
ensure that surgery is a viable option for pa-
tients with financial constraints.                JFP
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tAbLE
Surgery vs medical therapy for diabetes:  
Gastric bypass and biliopancreatic diversion 


















hba1c change from 
baseline* (%)
−25.18±20.89 −43.01±9.64 −8.39±9.93





100* 100* 27.3 
Bmi, body mass index. 
*P<0.01 for post hoc analysis comparing surgical arm to medical therapy.
†normalization of cholesterol was defined as a total cholesterol <201 mg/dl and 
hDl >40 mg/dl in men and >50 mg/dl in women (personal communication from author).
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